Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biogen Idec (NQ: BIIB ) 173.79 -0.21 (-0.12%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Biogen Idec < Previous 1 2 3 4 5 6 7 8 9 ... 40 41 Next > Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review November 01, 2024 The major indexes declined, but haven't fallen apart. Via Investor's Business Daily Biogen Analysts Slash Their Forecasts After Q3 Results October 31, 2024 Via Benzinga This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday October 31, 2024 Via Benzinga Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum October 30, 2024 The biotech giant also raised full-year EPS guidance. Via Investor's Business Daily Looking Into Biogen's Recent Short Interest October 22, 2024 Via Benzinga The Latest Analyst Ratings For Biogen October 10, 2024 Via Benzinga Looking Into Biogen's Recent Short Interest October 03, 2024 Via Benzinga Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights October 30, 2024 Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. Via Benzinga Biogen (BIIB) Q3 2024 Earnings Call Transcript October 30, 2024 BIIB earnings call for the period ending September 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook October 30, 2024 Biogen's Q2 revenue fell 3% to $2.47 billion exceeding estimates, with adjusted EPS of $4.08. Multiple sclerosis sales dipped, while new products buoyed performance. Via Benzinga This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock October 23, 2024 Fewer contenders means fewer constraints on expanding market share. Via The Motley Fool After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce October 17, 2024 Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and... Via Benzinga Topics Workforce Exposures Layoff Forecasting The Future: 20 Analyst Projections For Biogen September 23, 2024 Via Benzinga Key Takeaways From Biogen Analyst Ratings September 04, 2024 Via Benzinga Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock October 16, 2024 Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans... Via Benzinga Exposures Product Safety Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe October 14, 2024 Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory hurdles amid ongoing trials and safety concerns. Via Benzinga Large-Cap Stocks In Trouble - Sunday, Oct. 13 October 13, 2024 Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. Via Talk Markets After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study October 08, 2024 Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%. Via Benzinga Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year October 07, 2024 Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared... Via Benzinga Exposures Product Safety 1 Unstoppable Growth Stock Heading to $2 Trillion by 2030 September 28, 2024 It's hard to bet against this company right now. Via The Motley Fool Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate September 26, 2024 Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February... Via Benzinga Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial September 24, 2024 UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48... Via Benzinga Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know September 09, 2024 Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately. Via Benzinga Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?' September 09, 2024 Via Benzinga Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges September 09, 2024 Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highlight the benefits, but challenges with side effects, insurance, and diagnostics... Via Benzinga Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder September 04, 2024 Biogen announced topline data from the Phase 2/3 DEVOTE study showing a higher dose of nusinersen significantly improves motor function in treatment-naïve infants with spinal muscular atrophy, compared... Via Benzinga These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now August 31, 2024 This competitive showdown just saw one of the players hit a couple of bumps. Via The Motley Fool Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker August 28, 2024 Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space. Via Benzinga Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential August 27, 2024 PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets ranging from $84 to $185. Via Benzinga Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety August 26, 2024 The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 40 41 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
